Acquired resistance to drugs targeting receptor tyrosine kinases.
暂无分享,去创建一个
[1] D. Yee,et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. , 2008, The Journal of clinical investigation.
[2] A. Trumpp,et al. Mechanisms of Disease: cancer stem cells—targeting the evil twin , 2008, Nature Clinical Practice Oncology.
[3] William Pao,et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.
[4] A. Lane,et al. Histone deacetylase inhibitors in cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] N. Anderson,et al. The Mitogenic Action of Insulin-like Growth Factor I in Normal Human Mammary Epithelial Cells Requires the Epidermal Growth Factor Receptor Tyrosine Kinase* , 2004, Journal of Biological Chemistry.
[6] P. Zahradka,et al. Tyrosine kinase-independent activation of extracellular-regulated kinase (ERK) 1/2 by the insulin-like growth factor-1 receptor. , 2011, Cellular signalling.
[7] C. Arteaga,et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. , 2002, Cancer research.
[8] S. Keir,et al. Combination testing (Stage 2) of the Anti‐IGF‐1 receptor antibody IMC‐A12 with rapamycin by the pediatric preclinical testing program , 2012, Pediatric blood & cancer.
[9] C. Kahn,et al. A Kinase-Independent Role for Unoccupied Insulin and IGF-1 Receptors in the Control of Apoptosis , 2010, Science Signaling.
[10] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[11] P. Mehlen. Dependence Receptors: The Trophic Theory Revisited , 2010, Science Signaling.
[12] S. Rosenzweig,et al. Paradoxical effects of the phage display-derived peptide antagonist IGF-F1-1 on insulin-like growth factor-1 receptor signaling. , 2006, Biochemical pharmacology.
[13] Richard Gorlick,et al. Initial testing (stage 1) of the IGF‐1 receptor inhibitor BMS‐754807 by the pediatric preclinical testing program , 2011, Pediatric blood & cancer.
[14] H. Gronemeyer,et al. Towards novel paradigms for cancer therapy , 2011, Oncogene.
[15] P. Atadja,et al. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cells , 2007, Molecular Cancer Therapeutics.
[16] R. Nahta,et al. Herceptin: mechanisms of action and resistance. , 2006, Cancer letters.
[17] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[18] S. Goodin. Erlotinib: Optimizing Therapy with Predictors of Response? , 2006, Clinical Cancer Research.
[19] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[20] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.
[21] P. Seeburg,et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.
[22] A. Berns,et al. Drugging Drug Resistance , 2010, Cell.
[23] Nathanael Gray,et al. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors , 2009, Nature Reviews Drug Discovery.
[24] J. Fargnoli,et al. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. , 2010, Cancer research.
[25] Donna Neuberg,et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.
[26] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[27] Lesley Seymour,et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.
[28] F. E. Bertrand,et al. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis , 2004, Leukemia.
[29] Brent M. Nowak,et al. Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma , 2011, Molecular Cancer Therapeutics.
[30] J. Mestan,et al. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. , 2005, Blood.
[31] K. Helin,et al. Characterization of the retinoblastoma binding proteins RBP1 and RBP2. , 1993, Oncogene.
[32] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[33] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[34] M. Clynes,et al. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] M. Deininger,et al. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. , 2007, Blood.
[36] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[37] M. Slomiany,et al. Hypoxia-Inducible Factor-1-Dependent and -Independent Regulation of Insulin-Like Growth Factor-1-Stimulated Vascular Endothelial Growth Factor Secretion , 2006, Journal of Pharmacology and Experimental Therapeutics.
[38] C. Sawyers,et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[39] S. Ethier,et al. EGFR/Met association regulates EGFR TKI resistance in breast cancer , 2010, Journal of molecular signaling.
[40] Pixu Liu,et al. Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.
[41] Peter T. Yu,et al. IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration. , 2011, Carcinogenesis.
[42] P. Johnston,et al. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non–small cell lung cancer cells , 2006, Molecular Cancer Therapeutics.
[43] D. Gary Gilliland,et al. The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase , 2007, Cell.
[44] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[45] R. Pestell,et al. The type 1 insulin-like growth factor receptor and resistance to DACH1 , 2011, Cell cycle.
[46] D. Dillon,et al. IQGAP1 Protein Binds Human Epidermal Growth Factor Receptor 2 (HER2) and Modulates Trastuzumab Resistance* , 2011, The Journal of Biological Chemistry.
[47] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[48] M. Meyerson,et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.
[49] J. Mestan,et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.
[50] P. Mehlen,et al. Dependence receptors: a new paradigm in cell signaling and cancer therapy , 2010, Oncogene.
[51] Y. Lu,et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.
[52] J. Melo,et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.
[53] L. Helman,et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism , 2007, Oncogene.
[54] H. Ji,et al. Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation‐targeted lung cancer therapy , 2010, Cancer science.
[55] C. Pothoulakis,et al. Insulin-like Growth Factor-1 Receptor Transactivation Modulates the Inflammatory and Proliferative Responses of Neurotensin in Human Colonic Epithelial Cells* , 2011, The Journal of Biological Chemistry.
[56] Y. Yatabe,et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. , 2008, Cancer research.
[57] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] E. Rozengurt,et al. Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer , 2010, Clinical Cancer Research.
[59] L. VanWagner,et al. Activation of the Insulin-like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma Cells , 2011, Molecular Cancer Therapeutics.
[60] B. Druker,et al. Oncogenes and Tumor Suppressors (795 articles) , 2004 .
[61] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[62] Jessica E. Bolden,et al. Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.
[63] H. Atreya,et al. Defining the pathway to insulin-like growth factor system targeting in cancer. , 2010, Biochemical pharmacology.
[64] Yi Shen,et al. Trastuzumab Regulates IGFBP-2 and IGFBP-3 to Mediate Growth Inhibition: Implications for the Development of Predictive Biomarkers for Trastuzumab Resistance , 2011, Molecular Cancer Therapeutics.
[65] M. Slomiany,et al. Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. , 2007, Cancer letters.